Patent · US Active

BTK Inhibitors

US9718828B2 · kind B2 · utility

6Cited by
6References
15Claims
0Family size

Assignees

Inventors

Key dates

Filing dateAug 30, 2016
Grant dateAug 1, 2017
Priority date—
Expiry dateAug 30, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.